Merck Receives Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab) Regimens as Treatment for Patients With Two Types of Gynecologic Cancers
Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced ...
HealthDay on MSN1d
Pembrolizumab + Chemo Beneficial for Early-Stage Triple-Negative Breast Cancer
For patients with early-stage triple-negative breast cancer, neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant ...
Medscape2d
Pembrolizumab Approved With Chemotherapy for Malignant Pleural Mesothelioma
Pembrolizumab (Keytruda, Merck) has picked up another indication — this time for the first-line treatment of unresectable ...
Summit Therapeutics Bests Merck's Top Selling Drug In Phase III Trial
Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...
Ten-Year Data for Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Sustained Overall Survival Benefit Versus Ipilimumab in Advanced Melanoma
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced long-term overall survival (OS) data ...
Monthly Prescribing Reference23d
Merck Ends Pembrolizumab Trials for NSCLC, Cutaneous Squamous Cell Carcinoma
Merck has made the decision to end 2 clinical trials evaluating its programmed death receptor-1 (PD-1)-blocking antibody, Keytruda ® (pembrolizumab). The Company is discontinuing the phase 3 ...
Pharmabiz1mon
Merck to discontinue phase 3 KeyVibe-008 trial of fixed-dose combination of vibostolimab and pembrolizumab in patients with extensive-stage SCLC
The trial is evaluating the investigational fixed-dose combination (coformulation) of vibostolimab, an anti-TIGIT antibody, and pembrolizumab (Keytruda), Merck’s anti-PD-1 therapy, in combination ...
precisionmedicineonline6d
Merck's Keytruda Added to Adjuvant Chemo Benefits Newly Diagnosed Endometrial Cancer Subpopulation
The combination did not benefit a biomarker unselected population, but those with mismatch repair-deficient tumors had extended disease-free survival.
Yahoo Finance6d
Ten-Year Data for Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Sustained Overall Survival Benefit Versus Ipilimumab in Advanced Melanoma
At 10 years, more than one-third (34.0%) of patients with advanced melanoma were alive after treatment with KEYTRUDA, compared to 23.6% of patients treated with ipilimumab RAHWAY, N.J., September 15, ...